This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2014 May;24(5):276-82.

doi: 10.1097/FPC.0000000000000040.

PharmGKB summary: abacavir pathway

Julia M Barbarino¹, Deanna L Kroetz, Russ B Altman, Teri E Klein

Affiliations

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford cDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.

PMID: 24625462
PMCID: PMC4074515
DOI: 10.1097/FPC.0000000000000040

PharmGKB summary: abacavir pathway

Julia M Barbarino et al. Pharmacogenet Genomics. 2014 May.

. 2014 May;24(5):276-82.

doi: 10.1097/FPC.0000000000000040.

Authors

Julia M Barbarino¹, Deanna L Kroetz, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford cDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.

PMID: 24625462
PMCID: PMC4074515
DOI: 10.1097/FPC.0000000000000040

No abstract available

PubMed Disclaimer

Figures

Fig. 1 — Fig. 1
Schematic representation of abacavir pharmacokinetics and pharmacodynamics. The potential mechanism of an abacavir hypersensitivity reaction is also shown and is drawn using dashed lines as it is not currently well established. A fully interactive version is available online at http://www.pharmgkb.org/pathway/PA166104634.

Fig. 2 — Fig. 2
Structures for abacavir, CBV-TP, and deoxyguanosine triphosphate (dGTP). Note the similarities in structure between CBV-TP and dGTP, excluding the absence of the critical free 3’-OH group on the deoxyribose sugar ring in CBV-TP. This absence prevents the addition of any additional nucleotides and blocks further viral DNA synthesis. CBV-TP, (–)-carbovir 5’-triphosphate.

See this image and copyright information in PMC

Similar articles

The importance of being modest--reflections on the pharmacogenetics of abacavir.
Lindpaintner K. Lindpaintner K. Pharmacogenomics. 2002 Nov;3(6):835-8. doi: 10.1517/14622416.3.6.835. Pharmacogenomics. 2002. PMID: 12437485 Review. No abstract available.
Abacavir pharmacogenetics--from initial reports to standard of care.
Martin MA, Kroetz DL. Martin MA, et al. Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3. Pharmacotherapy. 2013. PMID: 23649914 Free PMC article. Review.
Treatment of Asian flush with abacavir.
Sanaei-Zadeh H. Sanaei-Zadeh H. Med Hypotheses. 2011 Aug;77(2):313. doi: 10.1016/j.mehy.2011.05.025. Med Hypotheses. 2011. PMID: 21684695 No abstract available.
Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
Cargnin S, Jommi C, Canonico PL, Genazzani AA, Terrazzino S. Cargnin S, et al. Pharmacogenomics. 2014 May;15(7):963-76. doi: 10.2217/pgs.14.52. Pharmacogenomics. 2014. PMID: 24956250
Successful translation of pharmacogenetics into the clinic: the abacavir example.
Phillips E, Mallal S. Phillips E, et al. Mol Diagn Ther. 2009;13(1):1-9. doi: 10.1007/BF03256308. Mol Diagn Ther. 2009. PMID: 19351209 Review.

See all similar articles

Cited by

The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolution.
Chazot A, Zimberger C, Feracci M, Moussa A, Good S, Sommadossi JP, Alvarez K, Ferron F, Canard B. Chazot A, et al. PLoS Biol. 2024 Aug 27;22(8):e3002743. doi: 10.1371/journal.pbio.3002743. eCollection 2024 Aug. PLoS Biol. 2024. PMID: 39190717 Free PMC article.
Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.
Yu ZJ, Mosher EP, Bumpus NN. Yu ZJ, et al. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:565-585. doi: 10.1146/annurev-pharmtox-021320-111248. Epub 2020 Sep 22. Annu Rev Pharmacol Toxicol. 2021. PMID: 32960701 Free PMC article. Review.
Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K-specific inhibition.
Baldwin ET, Götte M, Tchesnokov EP, Arnold E, Hagel M, Nichols C, Dossang P, Lamers M, Wan P, Steinbacher S, Romero DL. Baldwin ET, et al. Proc Natl Acad Sci U S A. 2022 Jul 5;119(27):e2200260119. doi: 10.1073/pnas.2200260119. Epub 2022 Jun 30. Proc Natl Acad Sci U S A. 2022. PMID: 35771941 Free PMC article.
Pharmacogenetics of the Treatment of Neglected Diseases.
Cabral TB, de Oliveira AC, Melo GC, Rodrigues-Soares F. Cabral TB, et al. Genes (Basel). 2025 Jan 5;16(1):54. doi: 10.3390/genes16010054. Genes (Basel). 2025. PMID: 39858601 Free PMC article. Review.
Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women.
Pearce CL, Stram D, Wiensch A, Frasco MA, Kono N, Den Berg DV, Anastos K, Cohen MH, DeHovitz J, Golub ET, Tamraz B, Liu C, Mack WJ. Pearce CL, et al. Int J HIV AIDS Res. 2017;4(3):154-160. doi: 10.19070/2379-1586-1700031. Epub 2017 Sep 5. Int J HIV AIDS Res. 2017. PMID: 29577081 Free PMC article.

See all "Cited by" articles

References

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012. 308:387–402. - PubMed
1. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47:351–371. - PubMed
1. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91:734–738. - PMC - PubMed
1. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732. - PubMed
1. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS. 1999;13:1419–1420. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations